D.E. Shaw & Co’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-16,846
| Closed | -$62K | – | 3945 |
|
|
2017
Q4 | $62K | Buy |
16,846
+2,400
| +17% | +$9.83K | ﹤0.01% | 3525 |
|
|
2017
Q3 | $59K | Sell |
14,446
-2,516
| -15% | -$9.63K | ﹤0.01% | 3398 |
|
|
2017
Q2 | $63K | Sell |
16,962
-49,697
| -75% | -$197K | ﹤0.01% | 3295 |
|
|
2017
Q1 | $276K | Buy |
66,659
+53,696
| +414% | +$226K | ﹤0.01% | 3001 |
|
|
2016
Q4 | $56K | Sell |
12,963
-4
| -0% | -$26 | ﹤0.01% | 3377 |
|
|
2016
Q3 | $128K | Sell |
12,967
-1,820
| -12% | -$12.9K | ﹤0.01% | 3266 |
|
|
2016
Q2 | $83K | Sell |
14,787
-6,539
| -31% | -$44.4K | ﹤0.01% | 3272 |
|
|
2016
Q1 | $163K | Sell |
21,326
-32,896
| -61% | -$253K | ﹤0.01% | 3228 |
|
|
2015
Q4 | $722K | Sell |
54,222
-12,507
| -19% | -$215K | ﹤0.01% | 2859 |
|
|
2015
Q3 | $1.1M | Sell |
66,729
-24,119
| -27% | -$494K | ﹤0.01% | 2540 |
|
|
2015
Q2 | $2.04M | Sell |
90,848
-105,676
| -54% | -$1.67M | ﹤0.01% | 2204 |
|
|
2015
Q1 | $1.92M | Buy |
196,524
+40,449
| +26% | +$397K | ﹤0.01% | 2043 |
|
|
2014
Q4 | $1.78M | Buy |
156,075
+16,969
| +12% | +$184K | ﹤0.01% | 2366 |
|
|
2014
Q3 | $1.6M | Sell |
139,106
-26,211
| -16% | -$400K | ﹤0.01% | 2404 |
|
|
2014
Q2 | $3.21M | Buy |
165,317
+44,315
| +37% | +$782K | ﹤0.01% | 1935 |
|
|
2014
Q1 | $2.17M | Buy |
121,002
+30,949
| +34% | +$508K | ﹤0.01% | 2304 |
|
|
2013
Q4 | $951K | Buy |
90,053
+6,838
| +8% | +$76.4K | ﹤0.01% | 3215 |
|
|
2013
Q3 | $1.03M | Buy |
83,215
+15,835
| +24% | +$167K | ﹤0.01% | 3018 |
|
|
2013
Q2 | $630K | Buy |
+67,380
| New | +$865K | ﹤0.01% | 3077 |
|
D.E. Shaw & Co's CASC Position: Q1 2018 in Review
D.E. Shaw & Co sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 16,846 shares — an estimated $62K sold.
D.E. Shaw & Co first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $3.21M in Q2 2014. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- D.E. Shaw & Co reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- D.E. Shaw & Co sold 16,846 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $62K.
- D.E. Shaw & Co first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- D.E. Shaw & Co's Cascadian Therapeutics, Inc. position peaked at $3.21M in Q2 2014.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on D.E. Shaw & Co's 13F filing for Q1 2018, filed 15 May 2018.